Comment by jmward01
No, my argument isn't that this wouldn't be used, it is that by using it there will be overage in quality of care above 'good enough' for the same or similar cost. That will result in the most expensive resources being reduced until quality of care is back to 'good enough' at less cost. It isn't a stretch to imagine that a tool like this would lead to a reduction in nursing staff since they can make rounds more effective and now don't need as many people to get the same level of quality job done.
But I think that's a wrong way to look at it. Or rather, it posits that we're at a point we truly consider good enough independent of cost.
It's entirely possible that we want better healthcare outcomes - all the historical trends point to that - but that we're more or less out of ideas how to get there on the cheap. This might be a new possibility.
In your model, why do we get improved, costlier insulin if the old thing was good enough? Because we actually want to pay more if it works better, and it doesn't mean we cut something else to make up for it. You just pay more in taxes in a subsidized model, or pay more at the pharmacy with private healthcare. There's a drug manufacturer profit motive in there, but it holds true in the added-cost ML scenario too.